Epitomics, Inc.

Cepheid Corporation

Stacey Ellen Wallace

Fernando Jose Rebelo Do Couto

Kristin Beth Hendricks

Russell G Higuchi

Edwin Wei-Lung Lai

Leena McCann

Guo-Liang Yu

Chris Lykke

Leena Mccann

Fernando Jose Couto

Compositions and methods for detecting bladder cancer are provided. In some embodiments, methods of monitoring recurrence of bladder cancer are provided. In some embodiments, the methods comprise detecting a set of markers consisting of CRH, IGF2, KRT20, and ANXA10.

Methods of detecting bladder cancer

Compositions and methods for detecting bladder cancer are provided. In some embodiments, methods of detecting low grade bladder cancer are provided. In some embodiments, methods of monitoring recurrence of bladder cancer are provided. In some embodiments, the methods comprise detecting androgen receptor (AR) and/or uroplakin 1B (UPK1B).

The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications.

Methods for screening and engineering antibodies

Compositions and methods for detecting markers associated with bladder cancer

The invention provides monoclonal antibodies that neutralize TNF&#x3b1; activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNF&#x3b1; activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications.

TNF&#x3b1;-neutralizing antibodies

Growing community of inventors

Sunnyvale, CA, United States of America

Stacey Ellen Wallace